Biomarker Discovery, Quantitation, and Analysis with Multiplex Immunoassays
- Broadcast Date:
Thursday, September 25, 2014
1 PM EDT, 10 AM PDT
REGISTRATION IS FREE
Scientists studying biomarkers associated with human diseases and drug responses commonly use targeted immunoassays for marker detection and quantitation. Challenges associated with conventional detection methods such as Western blotting and ELISAs include limitations imposed by small sample volume due to use of rodent models and the need for greater sensitivity than conventional test formats.
The introduction of multiplex xMAP® technology (Luminex) that combines advanced fluidics, optics, and digital signal processing with microsphere technology has enabled multiplexed assay capabilities and enables acquisition of more data in less time than other bioassay formats, with comparable results to ELISA. Featuring a flexible, open-architecture design, xMAP can be configured to perform a wide variety of bioassays quickly, cost-effectively, and accurately.
Recently, for example, scientists have applied xMAP technology to detection and expression of cytokine expression and secretion in lymphocyte samples from mouse and human sources, detecting over 20 different cytokines in samples smaller than 50 uL. This technology has also allowed assessment of cytokine expression in human diseases, before and after immunization and in the healthy general population, as well as the study of various mouse models of autoimmune diseases.
This multiplexed cytokine assay allows generation of large amounts of data and therefore new analyses, which result in new insights into the roles of cytokines in health and disease.
In this webinar, investigators will describe how Thermo Fisher Scientific’s Cytokine Human 30-Plex Panel for the Luminex platform, was used to demonstrate pharmacological inhibition of G protein-coupled estrogen receptor (GPER) as measured by a decrease in pro-inflammatory cytokines. Scientists will also describe how ongoing multiplex assay development for cancer-specific cytokine and autoantibody immunoassays may enable differentiation of lung cancer subtypes in patients.
In this webinar you will learn:
How, by measuring 30 analytes simultaneously, the Luminex assay panel helps provide more data from each sample, saving both money and time compared to more traditional systems (such as ELISA) used in research.
How multiplex cytokine kits can detect changes in proinflammatory cytokines in very small volumes of blood samples (less than 50 uL).
How one lab has used multiplex cytokine kits to detect rapid and transient activation of intracellular responses of the GPER to agonist binding.
How one multiplex assay developer continues to expand applications of this technology to include disease-specific biomarkers for prognostic applications in lung cancer.
Who Should Attend:
Drug development scientists
Core laboratory scientists
Scientists studying mechanisms of inflammatory and metabolic diseases
A live Q&A session will follow the presentations,
offering you a chance to pose questions to our expert panelists.